Generalized MG Patients Needed for UCB’s Global Rozanolixizumab Trial

Generalized MG Patients Needed for UCB’s Global Rozanolixizumab Trial

288192

Generalized MG Patients Needed for UCB’s Global Rozanolixizumab Trial

An international Phase 3 clinical trial assessing the efficacy, safety, and tolerability of rozanolixizumab as a treatment for generalized myasthenia gravis (MG) is currently recruiting participants at 114 study locations. Conducted by UCB BioSciences, the trial will determine if the treatment can reduce the typical signs and symptoms of generalized MG, according to the Muscular Dystrophy Association. To qualify for the study (NCT03971422), participants must be over age 18, diagnosed with generalized MG, have a minimum…

You must be logged in to read/download the full post.